ES2643628T3 - Reducción del riesgo de efectos patológicos de lesión cerebral traumática - Google Patents

Reducción del riesgo de efectos patológicos de lesión cerebral traumática Download PDF

Info

Publication number
ES2643628T3
ES2643628T3 ES10824055.7T ES10824055T ES2643628T3 ES 2643628 T3 ES2643628 T3 ES 2643628T3 ES 10824055 T ES10824055 T ES 10824055T ES 2643628 T3 ES2643628 T3 ES 2643628T3
Authority
ES
Spain
Prior art keywords
dha
composition
brain injury
weight
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10824055.7T
Other languages
English (en)
Spanish (es)
Inventor
Kevin Hadley
Terence. FEALEY
Julian E. Bailes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
West Virginia University
Original Assignee
DSM IP Assets BV
West Virginia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV, West Virginia University filed Critical DSM IP Assets BV
Application granted granted Critical
Publication of ES2643628T3 publication Critical patent/ES2643628T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
ES10824055.7T 2009-10-13 2010-10-13 Reducción del riesgo de efectos patológicos de lesión cerebral traumática Active ES2643628T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25123009P 2009-10-13 2009-10-13
US251230P 2009-10-13
PCT/US2010/052564 WO2011047095A1 (en) 2009-10-13 2010-10-13 Reducing the risk of pathological effects of traumatic brain injury

Publications (1)

Publication Number Publication Date
ES2643628T3 true ES2643628T3 (es) 2017-11-23

Family

ID=43876523

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10824055.7T Active ES2643628T3 (es) 2009-10-13 2010-10-13 Reducción del riesgo de efectos patológicos de lesión cerebral traumática

Country Status (8)

Country Link
US (2) US20110257267A1 (enExample)
EP (1) EP2488190B1 (enExample)
JP (3) JP2013507454A (enExample)
AU (1) AU2010306870B2 (enExample)
CA (1) CA2777367A1 (enExample)
ES (1) ES2643628T3 (enExample)
PL (1) PL2488190T3 (enExample)
WO (1) WO2011047095A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010306870B2 (en) 2009-10-13 2016-08-18 Dsm Ip Assets B.V. Reducing the risk of pathological effects of traumatic brain injury
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
US9269046B2 (en) * 2012-01-18 2016-02-23 Brainscope Company, Inc. Method and device for multimodal neurological evaluation
US8792974B2 (en) * 2012-01-18 2014-07-29 Brainscope Company, Inc. Method and device for multimodal neurological evaluation
CA3053187A1 (en) * 2017-02-09 2018-08-16 Bodhi Research & Development Inc. Cannabinoid-containing fatty acid formulations for treating disorders of the nervous system
US20190060268A1 (en) * 2017-08-25 2019-02-28 Increnovo, LLC Compositions and methods for preventing, alleviating, and treating neurological injury following head trauma
KR101946362B1 (ko) 2017-10-27 2019-02-11 파이코일바이오텍코리아(주) 뇌 염증성 질환 예방, 개선 또는 치료용 조성물
EP3710591A4 (en) * 2017-11-17 2021-07-14 Guangxi Xiaozao Agricultural Technology Co., Ltd. PRODUCTION OF MULTIPLE UNSATURED FATTY ACIDS FROM ALGAE
MX2021004051A (es) 2018-11-02 2021-06-04 Mara Renewables Corp Aceite de algas con valor nutricional mejorado.
MX429155B (es) 2019-06-20 2025-11-13 Aker Biomarine Human Ingredients As Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia
NL2023407B1 (en) 2019-06-28 2021-02-01 Aker Biomarine Antarctic As Parenteral lysophosphatidylcholine formulations
US20230398088A1 (en) * 2020-10-30 2023-12-14 The Trustees Of The University Of Pennsylvania Lipid Prophylactic Brain Injury Treatment
FR3132430B1 (fr) * 2022-02-09 2025-04-25 Polaris Composition comprenant un melange de dha et/ou d’epa et d’un phospholipide d’orgine vegetale

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
US6681403B2 (en) * 2000-03-13 2004-01-27 Robert M. Lyden Shin-guard, helmet, and articles of protective equipment including light cure material
US6469049B1 (en) * 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
US20060276373A1 (en) * 2004-01-23 2006-12-07 Bazan Nicolas G Neuroprotective complex for treatment of cerebral ischemia and injury
US20050164908A1 (en) 2004-01-23 2005-07-28 Ginsberg Myron D. Neuroprotective complex for treatment of cerebral ischemia and injury
US20060059605A1 (en) * 2004-09-22 2006-03-23 Xenith Athletics, Inc. Layered construction of protective headgear with one or more compressible layers of thermoplastic elastomer material
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
KR20130101596A (ko) * 2005-07-08 2013-09-13 마텍 바이오싸이언스스 코포레이션 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
WO2007100892A2 (en) * 2006-02-28 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Trojan horse immunotherapy
CN101049297B (zh) * 2006-04-06 2010-11-24 北京百慧生化制药有限责任公司 一种高dha型-乙酯和epa-乙酯的脂肪酸乙酯及其制造方法和制剂
US20090023808A1 (en) * 2007-06-29 2009-01-22 Martek Biosciences Corporation Production and Purification of Esters of Polyunsaturated Fatty Acids
WO2009057994A1 (en) 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
AU2010306870B2 (en) 2009-10-13 2016-08-18 Dsm Ip Assets B.V. Reducing the risk of pathological effects of traumatic brain injury
CN109350408B (zh) * 2018-12-11 2024-06-14 陶国民 过床护理椅

Also Published As

Publication number Publication date
JP6544747B2 (ja) 2019-07-17
CA2777367A1 (en) 2011-04-21
JP2016053065A (ja) 2016-04-14
JP2018021067A (ja) 2018-02-08
EP2488190A1 (en) 2012-08-22
US20110257267A1 (en) 2011-10-20
PL2488190T3 (pl) 2018-02-28
EP2488190A4 (en) 2013-03-27
AU2010306870A1 (en) 2012-05-03
AU2010306870A8 (en) 2012-06-28
WO2011047095A1 (en) 2011-04-21
US11413263B2 (en) 2022-08-16
JP6516158B2 (ja) 2019-05-22
JP2013507454A (ja) 2013-03-04
US20190046495A1 (en) 2019-02-14
EP2488190B1 (en) 2017-09-20
AU2010306870B2 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
US11413263B2 (en) Reducing the risk of pathological effects of traumatic brain injury
US20110086914A1 (en) Methods for Treating Traumatic Brain Injury
US20100203123A1 (en) Methods for improving cognitive function and decreasing heart rate
US20130137767A1 (en) Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid
WO2011097273A1 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
ES2218525T3 (es) Metodo y preparaciones farmaceuticas para el tratamiento de trastornos neurologicos.
ES2857173T3 (es) Aceites microbianos enriquecidos en ácidos grasos poliinsaturados
US20110177061A1 (en) Methods of treating and preventing neurological disorders using docosahexaenoic acid
CA3004879A1 (en) Method for treating mucositis
HK1172241A (en) Reducing the risk of pathological effects of traumatic brain injury
HK1172241B (en) Reducing the risk of pathological effects of traumatic brain injury
AU2010207929B2 (en) Methods for improving cognitive function and decreasing heart rate
US20240398747A1 (en) Anti-allergic agent
JP2024150428A (ja) アレルギー症状抑制剤
WO2011041710A2 (en) Docosahexaenoic acid gel caps
US20180085382A1 (en) Compositions and methods for cognitive health and memory
Thabit et al. The Effect of Nutrition in Promoting the Immune System Against Diseases: Covid-19 as a Case